IMM News: Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting La - 6th Jul 2022, 10:00pm

annb0t

Top 20
Immutep Limited

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office.

This new Japanese patent follows the grant of the equivalent European patent announced in October 202...

>>> Read more: Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
 
Top Bottom